Fistulas are debilitating complications of Crohn's disease (CD) that affect up to 50% of patients. We conducted a systematic review and meta-analysis of randomized controlled trials to assess the efficacy of treatments for fistulizing CD.
D evelopment of a fistula is a relatively common complication of Crohn's disease (CD), reported in 17%-50% of patients from population-based cohort studies. [1] [2] [3] Fistulae are abnormal, tunnel-like connections linking the bowel to neighboring epithelial surfaces and can result in persistent fecal or urinary seepage, pain and infection. Fistula pathogenesis is poorly understood, but it is hypothesized that mucosal and transmural inflammation, and possibly luminal bacteria, play a key role in fistula onset and perpetuation. [4] [5] [6] Risk factors include disease location and duration, rectal or colonic involvement, and young age at diagnosis. 1, 7 Consequently, impaired health-related quality of life, work productivity, sleep disturbance, and sexual dysfunction are frequently reported and collectively cause substantial morbidity. 8, 9 Classification of fistula is based on location and connection to contiguous organs or anatomic structures.
External fistula, including perianal and abdominal forms, are most common, respectively representing 55% and 6% of all cases. 3 Approximately one-third of fistula are internal, including enteroenteric, enterovesical, enterouterine, or enterovaginal types. Several systems are available to classify perianal fistula, including the Parks et al 10 and Hughes 11 criteria. A pragmatic, commonly used dichotomy is simple vs complex disease. Simple fistulae are low (ie, located below the dentate line) with a single external opening, in contrast to complex fistulae, which are high, may have multiple external openings, and may be associated with perianal abscess, connection to the vagina or bladder, rectal stenosis, or macroscopic proctitis. 12 Contemporary management of fistulizing CD has 2 objectives: to control infection and sepsis and to induce mucosal and fistula tract healing. Clinical guidelines for perianal fistulae recommend a multidisciplinary approach whereby surgical drainage or noncutting seton placement is performed before the initiation of pharmacotherapy. 8, [13] [14] [15] A short-term course of antibiotics is often followed by treatment with an immunosuppressive or biologic agent, administered alone or in combination. However, medical therapy alone is suboptimal, as many patients either fail to respond or experience fistula recurrence. 3, 16 While there are various adjunctive surgical techniques aimed at closing fistula tracts, 17 approximately 20% of CD patients with perianal fistula ultimately require proctectomy, 1, 3 and those with internal fistula often require surgical resection due to penetrating disease.
The efficacy of tumor necrosis factor a (TNF-a) antagonist therapy for treatment of fistulizing CD was established almost 15 years ago. Since that time, novel therapies and biologics with alternative mechanisms of action such as anti-integrins and inhibitors of the interleukin (IL) 12/23 pathway have emerged, although their efficacy in the management of fistulizing disease is uncertain. Accordingly, we performed a systematic review and meta-analysis of all published randomized controlled trials (RCTs) evaluating the efficacy of medical therapy for the management of fistulizing CD.
Methods

Protocol and Registration
This systematic review and meta-analysis was conducted using the methods described in the Cochrane Handbook of Systematic Reviews, 18 and reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. 19 
Eligibility Criteria
Eligible studies were randomized, placebo-, or active comparator-controlled trials that enrolled adult CD patients (16 years of age or older) with any form of fistulizing disease (ie, perianal, enterocutaneous, enteroenteric, enterovesical, enterovaginal, or enterouterine fistula). Interventions of interest included any pharmacological treatment administered alone or in combination. In the case of crossover trials, only firststage data were collected. Evaluation of surgical therapies, or their combination with medical therapies, were not evaluated as they have been previously described.
12,20
Outcomes
The primary outcome was the proportion of patients with fistula response. Secondary outcomes included the proportion of patients who achieved fistula remission, fistula resolution by diagnostic imaging (ie, magnetic resonance imaging or computed tomography), and maintenance of fistula closure. Data on health-related quality of life, incontinence, or similar functional outcomes were also extracted when available.
Search Strategy
The MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases were searched from inception to December 13, 2016 using predefined strategies (Supplementary Appendix 1). Language and date restrictions were not applied. The bibliographies of relevant articles retrieved from the electronic databases and conference proceedings from Digestive Disease Week and United European Gastroenterology Week (2012-2016) were hand-searched to ensure that all eligible studies were identified. Fully published papers as well as abstracts and conference proceedings were included.
Screening and Data Extraction
Two authors (M.J.L. and S.T.) screened the search results in parallel using the Covidence web tool. 21 The same 2 authors independently extracted information on the design, intervention, comparison, baseline characteristics, outcomes, and risk of bias of the included studies using a standardized spreadsheet (Excel, Microsoft Corp., Redmond, WA). Discrepancies encountered during screening or data extraction were resolved by discussion or recourse to a third author (C.E.P.). In the case of unclear or missing data, attempts were made to contact the original study authors for clarification.
Risk of Bias Assessment
The Cochrane risk of bias tool was used to assess the methodological quality of the included studies. 22 Seven domains (ie, random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of bias) were classified as being of unclear or low or high risk of bias.
Data Synthesis and Analysis
In studies with multiple dose arms, outcome data from the intervention groups were combined. If outcome data were reported at multiple time points, the predefined primary time point was used. Response and remission data were respectively combined regardless of whether the outcome definitions varied. All outcomes of interest were expressed dichotomously, with intervention effects reported as pooled risk ratios (RRs) and corresponding 95% confidence intervals (CIs). A fixedeffect model was used to pool data, however, we planned to use a random-effects model in the case of significant, unexplained heterogeneity. Data were analyzed according to the intention-to-treat principle, and statistical analyses were performed using RevMan 5.3 (Nordic Cochrane Centre for The Cochrane Collaboration, Copenhagen, Denmark).
A sensitivity analysis was conducted to determine whether excluding studies evaluating fistula disease activity as a secondary endpoint impacted the strength of the results. Subgroup analysis according to fistula type (ie, perianal vs other) was not prespecified, since we anticipated that most studies would focus on perianal fistulizing disease and the mode of action should be similar regardless of source or fistula origin.
Heterogeneity
The relative amount of observed heterogeneity was quantified using the I 2 statistic, which ranges from 0% to 100%. 23 A value of 0% indicates no observed heterogeneity, and substantial heterogeneity was defined as I 2 > 50%. 23 
Quality of the Evidence
The GRADE (Grade of Recommendations, Assessment, Development and Evaluation) approach was used to assess the quality of evidence for the primary and secondary outcomes. Results from RCTs were initially considered high quality, but potentially downgraded due to risk of bias, indirectness of evidence, unexplained heterogeneity, publication bias, or sparse data. 24 Outcomes with <35 events were reduced by 2 GRADE levels; outcomes with <300 events were reduced by 1 GRADE level.
Results
Search Results
Electronic database and hand searching identified a total of 802 records, from which 164 duplicates were removed. Of the remaining 638 records, 604 were deemed ineligible based on the information provided in the title and abstract. Full-text review was required for 34 records. Seven of the 34 records were excluded with reasons (Supplementary Table 1 ), while 27 studies enrolling a total of 2019 fistula patients met the eligibility criteria (Supplementary Figure 1) .
Description of Included Studies
A description of the included studies and definitions are provided in Table 1 . Twenty-four RCTs compared a drug intervention with placebo. Two antibiotics (ciprofloxacin and metronidazole) were evaluated in 1 study (n ¼ 25). 45 Thiopurines, including azathioprine and 6-mercaptopurine, were studied in 5 RCTs enrolling a total of 69 patients. 30, 33, 36, 37, 46 Tacrolimus was evaluated in 1 primary study of CD fistula and 1 subgroup analysis (n ¼ 58). 29, 40 Four TNF-a antagonists (adalimumab, CDP571, certolizumab pegol, and infliximab) were evaluated in 8 RCTs (n ¼ 821). 25, 28, 34, 38, 39, 41, 42, 44 One post hoc analysis of the GEMINI 2 RCT reported on the anti-a4b7 antibody vedolizumab (n ¼ 165). 26 Fistula results from 5 trials of ustekinumab, an anti-IL-12/23 antibody, were presented in 1 conference report (n ¼ 318). 43 Two RCTs assigned patients to mesenchymal stem cell therapy (n ¼ 233). 31, 32 AST-120, an oral intestinal spherical carbon adsorbent, was evaluated in 2 studies enrolling a total of 311 patients. 27, 35 Combination therapy with a TNF-a antagonist and an antibiotic vs treatment with a TNF-a antagonist and placebo was studied in 2 RCTs (n ¼ 96). 47, 48 Data from a single study comparing azathioprine to methotrexate (n ¼ 10) 49 could not be meta-analyzed.
The vast majority of included studies focused on patients with perianal fistulizing disease. Eleven RCTs solely enrolled patients with perianal fistula, 27, 29, 31, 32, 35, 43, 45, 47, 48 8 trials included patients with both perianal and abdominal fistula, 25, 28, 34, 37, [40] [41] [42] 49 and in 3 studies including various fistula types, the majority of patients were indicated to have perianal fistula. 30, 33, 44 Four additional studies included various fistula types, but did not specify whether the majority were perianal fistula, 26, 38, 39, 46 and in 1 study most patients had abdominal fistula (see Table 1 ). 36 
Risk of Bias Assessment
The results of the risk of bias assessment are presented in Supplementary Table 2. All included studies received low or unclear risk of bias appraisals except for Ardizzone et al, 49 an investigator-blind trial that was rated as high risk of bias for blinding of participants and selective reporting. (10) 94 5-ASA (55) ABX (30) CS (34) IM (40) TNF exposure (0) IFX (56) Placebo (29 (Figure 1 ). There was no observed heterogeneity (I 2 ¼ 0%) and the overall quality of evidence was considered low due to very sparse data (Supplementary Table 3) .
A total of 18% (3 of 17) of patients receiving antibiotics achieved fistula remission compared with 12.5% (1 of 8) of placebo patients. Again, the pooled RR, indicated that this effect was not statistically significant (RR, 1.20; 95% CI, 0.17-8.38; P ¼ .85) (Figure 2) . The overall quality of evidence for this outcome was considered low due to very sparse data (Supplementary Table 3) .
Thiopurines. Four studies assessing azathioprine or 6-mercaptopurine vs placebo reported on induction of fistula response. 30, 33, 36, 46 Thirty percent (12 of 40) of patients assigned to active treatment achieved fistula response compared with 16% (4 of 25) of placebo patients. The pooled RR, failed to show a statistically significant effect between groups (RR, 1.86; 95% CI, 0.73-4.75, P ¼ .20; Figure 1.1.) . There was no observed heterogeneity, and the quality of evidence was considered low due to very sparse data (Supplementary Table 3) .
With respect to induction of fistula remission, 29% (10 of 34) of patients receiving a thiopurine achieved remission compared with 9% (2 of 22) of patients receiving placebo. The pooled RR was 3.38 (95% CI, 0.76-15.71; P ¼ .11) (Figure 2 ), indicating no statistically significant difference in effect between treatment groups. The observed heterogeneity was not substantial, and the overall quality of evidence was considered low due to very sparse data (Supplementary Table 3 ).
Rosenberg 1975 was the only included study to report on maintenance of fistula response. 37 In this small study, the 1 fistula patient who responded to active therapy failed to maintain response, while the 1 fistula patient who responded to placebo successfully maintained response (Figure 3) . A reliable estimate of the RR for this study could not be estimated, and the quality of evidence was considered low due to very sparse data (Supplementary Table 3) .
One head-to-head trial of immunosuppressives was identified. 49 In Ardizzone et al, 49 67% (4 of 6) of patients receiving methotrexate achieved fistula remission compared with 30% (2 of 6) of patients receiving azathioprine (RR, 2.0; 95% CI, 0.56-7.09; P ¼ .28) (Supplementary Figure 3.1) . This effect was not statistically significant, and the quality of evidence was considered very low due to very sparse data and high risk of bias for blinding of participants and selective reporting (Supplementary Table 3 ).
Tacrolimus. Two trials reported on induction of fistula response, and fistula remission. 29, 40 Thirty-seven percent (10 of 27) and 10% (3 of 31) of tacrolimus and placebo patients achieved response, respectively (RR, 3.82; 95% CI, 1.17-12.40; P ¼ .03). The betweengroup difference in effect was statistically significant. Heterogeneity was low (I 2 ¼ 23%), and the quality of evidence was considered low due to very sparse data. With respect to fistula remission, 11% (3 of 27) of patients randomized to tacrolimus achieved remission compared with 6% (2 of 31) of placebo patients. The pooled estimate failed to demonstrate a statistically significant between-group difference (RR, 1.58; 95% CI, 0.33-7.51; P ¼ .57). No heterogeneity was observed, and the quality of evidence was considered low due to very sparse data.
TNF-a antagonists. Fistula response was reported in 6 trials of TNF-a antagonists. 28, 34, 38, 39, 41, 44 Forty-four percent (106 of 243) of patients receiving a TNF-a antagonist achieved fistula response compared with 28% (50 of 179) of placebo patients. The pooled RR was 1.45 (95% CI, 1.08-1.95, P ¼ .01), demonstrating a statistically significant effect in favor of TNF-a antagonist therapy. A low degree of heterogeneity was observed (I 2 ¼ 25%), and the quality of evidence was considered moderate due to sparse data.
Six RCTs evaluating TNF-a antagonists reported on the proportion of patients who achieved fistula remission. 28, 34, 38, 41, 42, 44 Thirty-four percent (90 of 267) of patients in the TNF-a antagonist therapy group achieved fistula remission compared with 16% (26 of 165) of patients in the placebo group. The pooled RR was 2.01 (95% CI, 1.36-2.97; P < .001) (Figure 2 ), demonstrating a statistically significant effect in favor of TNF-a antagonist therapy in comparison with placebo. There was no observed heterogeneity, and the quality of evidence was considered moderate due to sparse data (Supplementary Table 3 ).
Maintenance of fistula response was evaluated in 2 studies. 42, 44 A total of 43% (53 of 124) of patients receiving a TNF-a antagonist maintained response compared with 22% (28 of 129) of placebo patients. The between-group difference in effect was statistically significant (RR, 1.97; 95% CI, 1.34-2.89; P < .001) (Figure 3) . No heterogeneity was observed, and the quality of evidence was rated as moderate due to sparse data (Supplementary Table 3 ). The same 2 studies reported on maintenance of fistula remission. Thirty-five percent (43 of 124) of patients treated with a TNF-a antagonist maintained remission compared with 18% (23 of 129) of patients receiving placebo. The pooled RR was 1.94 (95% CI, 1.25-3.02; P ¼ .003) (Figure 4) , demonstrating a statistically significant effect in favor of TNF-a antagonist therapy. There was no observed heterogeneity, and the quality of evidence was considered moderate due to sparse data (Supplementary Table 3 ).
Vedolizumab. The GEMINI 2 trial was the only included study that assessed fistula healing among patients randomized to vedolizumab. In a post hoc analysis of data from the GEMINI 2 trial reported in abstract form, 26 28% (11 of 39) of patients in the vedolizumab group achieved fistula remission compared with 11% (2 of 18) of patients in the placebo group. However, the relative improvement in fistula remission with vedolizumab was not statistically significant (RR, 2.54; 95% CI, 0.63-10.29; P ¼ .19) (Figure 2 ). The evidence supporting this outcome was considered low due to paucity of data (Supplementary Table 3 ).
Ustekinumab. A post hoc pooled analysis of data from the CERTIFI, UNITI-1, and UNITI-2 trials (reported in abstract form) provided data on induction of fistula response and remission rates. 43 Twenty-four percent (39 of 161) of patients receiving ustekinumab responded to treatment vs 16% (12 of 77) of placebo patients. The pooled RR (1.55; 95% CI, 0.86-2.80) (Figure 1 ) revealed a numerically, but not statistically, significant effect in favor of ustekinumab. The quality of evidence for this outcome was considered moderate due to sparse data (Supplementary Table 3) .
For fistula remission, 23% (37 of 161) of patients assigned to ustekinumab achieved fistula remission compared with 13% (10 of 77) of placebo patients. The difference in effect between groups was not statistically significant (RR, 1.77; 95% CI, 0.93-3.37; P ¼ .08), and the quality of evidence was considered moderate due to sparse data (Supplementary Table 3) .
Two studies reported on maintenance of response. In the IM-UNIIT and CERTIFI-M trials, 54% (21 of 39) of patients assigned to active therapy maintained response compared with 27% (11 of 41) of placebo patients (RR, 1.82; 95% CI, 1.04-3.17; P ¼ .04), suggesting a statistically significant difference in favor of ustekinumab. The quality of evidence was considered low due to very sparse data (Supplementary Table 3) .
AST-120. Data from 2 trials of the oral spherical carbon adsorbent AST-120 were pooled for analysis. 27, 35 Among patients assigned to AST-120, 18% (27 of 149) had a response compared with 15% (24 of 157) of placebo patients. The pooled RR indicated that there was no statistically significant difference in effect between AST-120 and placebo (RR, 1.19; 95% CI, 0.72-1.97; P ¼ .50) ( Figure 2) ; however, the observed heterogeneity was high (I 2 ¼ 79%). Likewise, the pooled RR for induction of fistula remission failed to demonstrate a statistically significant between-group difference in effect (RR, 1.45; 95% CI, 0.79-2.66; P ¼ .22), and observed heterogeneity was also substantial (I 2 ¼ 66%) for this outcome. While Fukuda et al 27 reported a statistically significant treatment effect in favor of active treatment (RR, 3.70; 95% CI, 1.14-12.06), a large, multinational, follow-up study by Reinisch et al 35 failed to confirm these findings (RR, 0.84; 95% CI, 0.47-1.52). Potential explanations for the discordant results include differences among the study populations with respect to nationality, genetics, diet, age, body mass index, prior TNF-a antagonist exposure, and baseline disease activity. 35 Mesenchymal stem cell therapy. Two trials compared mesenchymal stem cell therapy to placebo for induction of fistula response. 31, 32 Sixty-six percent (80 of 122) of patients receiving stem cell injections responded vs 52% (58 of 111) of placebo patients. The pooled RR was 1.27 (95% CI, 1.02-1.59, P ¼ .03) (Figure 1) , indicating that stem cell therapy was effective for inducing fistula response. There was no observed heterogeneity for this outcome (I 2 ¼ 0%), and the overall quality of evidence was considered moderate due to sparse data.
Fifty-two percent (64 of 122) of patients in the stem cell therapy group achieved fistula remission vs 41% (45 of 111) of placebo patients. The pooled RR revealed that stem cell therapy was not more statistically effective than placebo for induction of fistula remission (RR, 1.31; 95% CI, 0.98-1.73, P ¼ .06) (Figure 2 ). There was no observed heterogeneity (I 2 ¼ 0%), and the overall quality of evidence was considered moderate due to sparse data.
Biologic Combined With Antibiotic vs Biologic Alone
Two trials compared combination therapy with a TNF-a antagonist and an antibiotic to TNF-a antagonist monotherapy. 47, 48 Seventy percent (32 of 46) of patients in the combination therapy group had fistula response compared with 44% (22 of 50) of patients in the monotherapy group. The pooled RR demonstrated that a TNF-a antagonist coupled with an antibiotic was more effective than a TNF-a antagonist administered alone for induction of fistula response (RR, 1.58; 95% CI, 1.09-2.28; P ¼ .01) (Supplementary Figure 2.1) . No heterogeneity was observed (I 2 ¼ 0%), and the overall quality of evidence was considered moderate due to sparse data. One study reported on fistula remission rates. Sixty-one percent (22 of 36) of patients receiving combination therapy achieved remission vs 32% (12 of 37) of patients assigned to placebo. This difference in effect was statistically significant (RR, 1.94; 95% CI, 1.14-3.29; P ¼ .01) ( Supplementary Figure 2. 2), and the overall quality of evidence was considered low due to very sparse data.
None of the included studies in this review presented fistula-specific data on resolution by diagnostic imaging, health-related quality of life, or functional outcomes.
Sensitivity Analysis
Ten of the 27 included studies evaluated fistula disease activity as the primary outcome and therefore exclusively enrolled patients with fistulizing CD, whereas in 17 trials fistula disease activity was assessed as a secondary outcome. Sensitivity analyses showed that omitting the 17 RCTs that studied fistula disease activity as a secondary outcome did not change the overall results (Supplementary Table 4.1) . Eleven of the 27 included studies solely included patients with perianal fistulae. Sensitivity analysis demonstrated that omitting the 16 RCTs with mixed fistula populations had a minimal impact on the overall results (Supplementary Table 4 .2).
Discussion
Development of novel therapies for the treatment of fistulizing disease is a large unmet need in the management of CD. At present, there are no Food and Drug Administration-approved pharmacotherapies for fistulizing CD. Accordingly, research priorities set by multidisciplinary organisations 8, 50 have underscored a critical need for drug development in this area.
In the current meta-analysis, 27 RCTs were identified, evaluating a total of 14 separate pharmacotherapies. Our key finding was, thus far, TNF-a antagonists are the only drug class proven to both induce and maintain fistula response and remission. As a class, they were associated with an approximately 1.5-fold increase in likelihood of induction of fistula response, and a 2-fold increase in likelihood of induction of fistula remission, maintenance of fistula response and maintenance of fistula remission. The largest effect estimates for both induction and maintenance of fistula response and fistula remission were observed for infliximab (RR, 2.40; 95% CI, 1.28-4.49; RR, 3.57; 95% CI, 1.38-9.25; RR, 1.88; 95% CI, 1.23-2.88; and RR, 1.79; 95% CI, 1.10-2.92, respectively). Direct comparisons between the TNF-a antagonists were not possible due to sparse data.
When combined with antibiotics, a statistically significant higher rate of induction of fistula response and remission was observed in comparison with a TNF-a antagonist administered alone. Future studies should focus on the efficacy of combination therapy with immunosuppressives and the relationship between TNF-a antagonist trough levels and response status within the context of treatment optimization for fistulizing CD.
While thiopurines were not found to be superior to placebo for induction of fistula response or remission, oral tacrolimus may be effective for induction of response. Unfortunately, the side effect profile associated with this agent has limited its use.
Recently, 2 additional biologic agents, ustekinumab (Stelara; Janssen Biotech, Horsham, PA) 51 and vedolizumab (Entyvio; Takeda, Deerfield, IL) 52 , have become available in routine clinical practice for the management of moderateto-severely active CD. Ustekinumab, a fully human IgG K monoclonal antibody that blocks the common p40 subunit of IL-12 and IL-23, was approved for the treatment of moderate-to-severely active CD on the basis of demonstrated efficacy for induction (UNITI-1 and UNITI-2) and maintenance (IM-UNITI) in both TNF-a antagonist naive and failure patients. 51 To date, no phase 4 trial is underway to specifically investigate its effectiveness for the treatment of fistulizing disease. In the absence such a study, a post hoc analysis of patients in the pivotal trials provides some signal of treatment efficacy for patients with perianal fistulizing CD. Pooled data from 1 phase 2 (CERTIFI) and 2 phase 3 induction trials (UNITI-1 and UNITI-2) of ustekinumab revealed a statistically significant 1.5-fold increase in the likelihood of inducing fistula response. While these data should be considered exploratory, the encouraging results warrant further investigation.
The a4b7 integrin antibody vedolizumab inhibits trafficking of subpopulations of T cells to the gut mucosa. In the pivotal registration trial, at week 6, 14.5% (vs 6.8% in placebo; P ¼ .02) and at week 52, 39.0% and 36.4% of patients who received vedolizumab every 8 and 4 weeks, respectively, were in clinical remission (vs 21.6% in the placebo group; P < .001 and P ¼ .004, respectively). Post hoc, exploratory analyses published in abstract form reporting on the efficacy of vedolizumab for induction of fistula remission (mixed fistula population) demonstrated a trend in favor of active treatment, although this was not statistically significant. The efficacy of vedolizumab for the induction and maintenance of perianal fistula response and remission is subject to a phase 4 clinical trial that is currently underway (NCT02630966).
Intralesional injection of stem cell therapy is a promising treatment for patients with refractory perianal fistulizing disease. The pooled analysis of a small trial of bone marrow derived mesenchymal stromal cells and a larger phase 3 trial of adipose derived stem cells using an a combined clinical and imaging endpoint demonstrated a 30% increase in the likelihood of achieving fistula remission over placebo. 31, 32 High rates of placebo remission were observed in the trial of adipose derived stem cells through surgical curettage and injection of saline in fistula tracts, indicating the importance of good adjunctive surgical techniques in the management of perianal fistulizing disease. A phase 3 trial is underway in North America (NCT03279081).
Several limitations of this analysis should be acknowledged. First, the review does not take surgical or combined medical-surgical treatments of fistulizing CD into account, as a comprehensive review of this topic already exists. 20 Second, given that fistulizing CD is a rare condition, the included RCTs are limited in number and size. Third, either the majority of, or all, patients in the eligible studies had perianal fistulizing disease, therefore it is unclear whether our findings are generalizable to all fistula types. A post hoc subgroup analysis of data from the ACCENT II study that assessed the efficacy and safety of infliximab for the treatment of rectovaginal fistula was the sole report identified that exclusively focused on a nonperianal fistula population. 53 Only results from the main ACCENT II study were pooled for meta-analysis in the current systematic review. Fourth, a small number of trials contained pooled results of mixed fistula populations, although it is reasonable to hypothesize that biological treatment effects are similar regardless of fistula origin. Fifth, results pertaining to the newer biologics, ustekinumab and vedolizumab, should be considered exploratory because they come from post hoc analyses published in abstract from involving a small number of patients. Finally, there was some heterogeneity in endpoint definitions for fistula response and remission, although this is previously summarized in the field of IBD 54 and initiatives are underway to develop core outcome sets to standardize outcome measures for clinical trials. 55 In this regard, recent development of the modified Van Assche index for the assessment of perianal fistulizing CD by magnetic resonance imaging represents an important initiative toward more efficient outcome measures. 56 In conclusion, TNF-a antagonists are the only drug class to demonstrate efficacy for induction and maintenance of fistula response and fistula remission. Injection of stem cell therapy into fistula tracts offers a promising therapy for those with fistulae resistant to conventional pharmacological treatment and more efficacy data are needed on the novel biologic agents ustekinumab and vedolizumab.
